Ua ʻāpono ʻia ka hōʻailona ʻehā o Ameile no ke kūʻai aku ʻana, e kuhikuhi ana i ka lāʻau lapaʻau adjuvant post-operative no ka maʻi kanesa māmā cell liʻiliʻi ʻole EGFR mutation-positive

Ma ka lā 9 o Mei, 2025, ua hoʻolaha ʻo Hansoh Pharmaceutical ua ʻae ʻia kahi hōʻailona hou no Ameile (nā papa almonertinib mesylate) no ke kūʻai aku ʻana. ʻO ka hōʻailona hou no ka mālama adjuvant o nā poʻe maʻi makua me ka maʻi ʻaʻai māmā ʻaʻole liʻiliʻi (NSCLC) nona nā puʻupuʻu i loaʻa i ka epidermal growth factor receptor (EGFR) exon 19 deletion a i ʻole exon 21 (L858R) mutations, a ua hana ʻia ka tumor resection. Loaʻa iā Ameile i kēia manawa ʻehā mau hōʻailona i ʻae ʻia ma Kina, e mālama ana i kona kūlana alakaʻi ma waena o nā hanauna ʻekolu o EGFR-TKI i hoʻomohala ʻia ma ka home.

ʻO ke kumu nui o kēia ʻae ʻia ʻana ma ke aʻo ʻana o ARTS (HS-10296-302), he hoʻokolohua lapaʻau randomized, double-blind, controlled, multicenter Phase III. Ua hōʻike ʻia nā hopena o ke aʻo ʻana ma ke ʻano he hōʻike waha ma ka 2025 American Association for Cancer Research (AACR) Annual Meeting.

Ua hōʻoia ka ʻikepili mai ke aʻo ʻana o ARTS i hōʻike ʻia ma ka Hālāwai Makahiki AACR 2025 no nā poʻe maʻi me ka pae II–IIIB EGFR-mutant NSCLC i ʻoki piha ʻia, hiki i ka lāʻau lapaʻau adjuvant me Ameile—inā pili—ke hoʻomaikaʻi nui i ke ola ʻole maʻi (DFS). Ua hōʻea ka helu DFS 2 makahiki i 90.2%, me ka HR o 0.17, a ua hiki ke hoʻokele ʻia ka ʻikepili palekana holoʻokoʻa. ʻO ka mea nui, ua hoʻopaʻa inoa wale ka haʻawina i nā poʻe maʻi Kina, e hōʻike ana i ka pono koʻikoʻi a me ka ʻikepili palekana hiki ke hoʻokele ʻia o ka EGFR-TKI i hoʻomohala ʻia ma ka home i loko o ka heluna kanaka Kina.

E pili ana iā ʻAmeile

Ma ke ʻano he EGFR-TKI hanauna ʻekolu mua loa o Kina, hōʻike ʻo Ameile (Aumolertinib Mesilate Tablets) i ka liposolubility maikaʻi a me ke kūpaʻa, e ʻae ana iā ia e komo maikaʻi i ka pale koko-lolo me ka haʻahaʻa o nā hopena ʻino. I kēia manawa, ua ʻae ʻia ʻo Ameile no ʻehā mau hōʻailona: ka lāʻau lapaʻau laina ʻelua o nā maʻi me ka NSCLC holomua kūloko a metastatic paha me ka mutation T790M, ka poʻe i holomua ma luna a ma hope paha o ka lāʻau EGFR-TKI; ka lāʻau lapaʻau laina mua no nā maʻi makua me ka NSCLC holomua kūloko a metastatic paha nona nā tumors i loaʻa ka EGFR exon 19 deletions a i ʻole exon 21 (L858R) pani mutation maikaʻi; ka mālama ʻana i nā maʻi me ka locally advanced, unresectable（Stage III）non-small cell lung cancer (“NSCLC”) nona ka maʻi i holomua ʻole ma hope o ka chemoradiotherapy platinum-based definitive nona nā tumors i loaʻa ka epidermal growth factor receptor (“EGFR”) exon 19 deletions a i ʻole exon 21 (L858R) pani mutations; lāʻau lapaʻau adjuvant o nā poʻe maʻi makua me ka maʻi ʻaʻai māmā ʻaʻole liʻiliʻi (NSCLC) nona nā puʻupuʻu i loaʻa i ka epidermal growth factor receptor (EGFR) exon 19 deletion a i ʻole exon 21 (L858R) mutations, a ua hana ʻia ka ʻoki ʻana o ka puʻupuʻu.

I kēia manawa, nui nā hoʻokolohua lapaʻau o nā ʻenehana anti-cancer hou ma Kina e ʻimi nei i nā maʻi. I ke kūkākūkā ʻana i nā lāʻau lapaʻau a me nā ʻenehana hou, hiki iā ʻoe ke hoʻokaʻaʻike aku i ka Beijing South Region Oncology Hospital International Department.

Helu Kelepona：4008803716

Email：myimmnet@163.com